Danaher [DHR] vs Idexx Laboratories [IDXX] Detailed Stock Comparison
Danaher
NYSE
Loading...
Idexx Laboratories
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Danaher wins in 10 metrics, Idexx Laboratories wins in 9 metrics, with 0 ties. Danaher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Danaher | Idexx Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 39.25 | 51.08 | Danaher |
| Price-to-Book Ratio | 2.55 | 34.07 | Danaher |
| Debt-to-Equity Ratio | 35.45 | 84.81 | Danaher |
| PEG Ratio | -1.05 | 1.05 | Danaher |
| EV/EBITDA | 19.79 | 37.47 | Danaher |
| Profit Margin (TTM) | 14.21% | 24.41% | Idexx Laboratories |
| Operating Margin (TTM) | 20.12% | 33.62% | Idexx Laboratories |
| EBITDA Margin (TTM) | 20.12% | 33.62% | Idexx Laboratories |
| Return on Equity | 6.68% | 64.87% | Idexx Laboratories |
| Return on Assets (TTM) | 4.01% | 23.26% | Idexx Laboratories |
| Free Cash Flow (TTM) | $5.30B | $798.08M | Danaher |
| 1-Year Return | -22.11% | 32.69% | Idexx Laboratories |
| Price-to-Sales Ratio (TTM) | 5.55 | 12.29 | Danaher |
| Enterprise Value | $148.83B | $52.19B | Danaher |
| EV/Revenue Ratio | 6.20 | 12.93 | Danaher |
| Gross Profit Margin (TTM) | 59.35% | 62.62% | Idexx Laboratories |
| Revenue per Share (TTM) | $33 | $50 | Idexx Laboratories |
| Earnings per Share (Diluted) | $4.74 | $12.14 | Idexx Laboratories |
| Beta (Stock Volatility) | 0.78 | 1.56 | Danaher |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Danaher vs Idexx Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Danaher | -1.20% | 15.91% | 3.21% | 3.87% | 2.52% | -8.48% |
| Idexx Laboratories | 2.21% | 2.53% | -0.88% | 16.79% | 48.70% | 55.03% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Danaher | -22.11% | -11.63% | 4.95% | 253.56% | 656.04% | 1,076.34% |
| Idexx Laboratories | 32.69% | 90.21% | 58.20% | 755.96% | 1,949.27% | 3,904.04% |
News Based Sentiment: Danaher vs Idexx Laboratories
Danaher
News based Sentiment: MIXED
Danaher delivered a mixed month, with strong Q2 results and positive developments in AI and potential tariff benefits offset by challenges in the Life Sciences segment and differing analyst opinions. The company's overall outlook remains positive, but investors should monitor key areas for potential risks and opportunities.
Idexx Laboratories
News based Sentiment: MIXED
IDEXX demonstrated continued strong financial performance and raised its long-term outlook, but insider selling and mixed institutional activity introduced some caution. The company's overall trajectory remains positive, but these factors warrant investor attention and monitoring as we approach the Q3 earnings report on October 30, 2025.
Performance & Financial Health Analysis: Danaher vs Idexx Laboratories
| Metric | DHR | IDXX |
|---|---|---|
| Market Information | ||
| Market Cap | $136.50B | $49.74B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 4,577,060 | 409,804 |
| 90 Day Avg. Volume | 3,756,927 | 397,098 |
| Last Close | $210.33 | $633.84 |
| 52 Week Range | $171.00 - $279.41 | $356.14 - $688.12 |
| % from 52W High | -24.72% | -7.89% |
| All-Time High | $296.06 (Sep 06, 2021) | $706.95 (Jul 26, 2021) |
| % from All-Time High | -28.96% | -10.34% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.03% | 0.11% |
| Quarterly Earnings Growth | -0.39% | 0.45% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.24% |
| Operating Margin (TTM) | 0.20% | 0.34% |
| Return on Equity (TTM) | 0.07% | 0.65% |
| Debt to Equity (MRQ) | 35.45 | 84.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $73.10 | $18.20 |
| Cash per Share (MRQ) | $4.13 | $2.06 |
| Operating Cash Flow (TTM) | $6.17B | $905.81M |
| Levered Free Cash Flow (TTM) | $3.88B | $625.74M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Danaher vs Idexx Laboratories
| Metric | DHR | IDXX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 39.25 | 51.08 |
| Forward P/E | 22.20 | 51.85 |
| PEG Ratio | -1.05 | 1.05 |
| Price to Sales (TTM) | 5.55 | 12.29 |
| Price to Book (MRQ) | 2.55 | 34.07 |
| Market Capitalization | ||
| Market Capitalization | $136.50B | $49.74B |
| Enterprise Value | $148.83B | $52.19B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.20 | 12.93 |
| Enterprise to EBITDA | 19.79 | 37.47 |
| Risk & Other Metrics | ||
| Beta | 0.78 | 1.56 |
| Book Value per Share (MRQ) | $73.10 | $18.20 |
Financial Statements Comparison: Danaher vs Idexx Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DHR | IDXX |
|---|---|---|
| Revenue/Sales | $5.74B | $998.43M |
| Cost of Goods Sold | $2.23B | $375.05M |
| Gross Profit | $3.51B | $623.38M |
| Research & Development | $379.00M | $59.06M |
| Operating Income (EBIT) | $1.27B | $316.53M |
| EBITDA | $1.87B | $351.81M |
| Pre-Tax Income | $1.13B | $310.08M |
| Income Tax | $175.00M | $67.41M |
| Net Income (Profit) | $954.00M | $242.68M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DHR | IDXX |
|---|---|---|
| Cash & Equivalents | $1.99B | $163.97M |
| Total Current Assets | $9.53B | $1.32B |
| Total Current Liabilities | $6.65B | $1.14B |
| Long-Term Debt | $15.98B | $546.80M |
| Total Shareholders Equity | $50.86B | $1.45B |
| Retained Earnings | $44.91B | $5.58B |
| Property, Plant & Equipment | N/A | $833.62M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DHR | IDXX |
|---|---|---|
| Operating Cash Flow | $1.47B | $235.07M |
| Capital Expenditures | $-239.00M | $-30.03M |
| Free Cash Flow | $1.05B | $207.94M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-1.08B | $-400.89M |
Short Interest & Institutional Ownership Analysis
| Metric | DHR | IDXX |
|---|---|---|
| Shares Short | 9.53M | 2.12M |
| Short Ratio | 2.85 | 5.41 |
| Short % of Float | 0.01% | 0.03% |
| Average Daily Volume (10 Day) | 4,577,060 | 409,804 |
| Average Daily Volume (90 Day) | 3,756,927 | 397,098 |
| Shares Outstanding | 719.10M | 81.60M |
| Float Shares | 637.13M | 79.12M |
| % Held by Insiders | 0.11% | 0.01% |
| % Held by Institutions | 0.83% | 0.97% |
Dividend Analysis & Yield Comparison: Danaher vs Idexx Laboratories
| Metric | DHR | IDXX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |